Nothing Special   »   [go: up one dir, main page]

DK3294323T3 - Adeno-associeret virus til terapeutisk indgivelse til centralnervesystemet - Google Patents

Adeno-associeret virus til terapeutisk indgivelse til centralnervesystemet Download PDF

Info

Publication number
DK3294323T3
DK3294323T3 DK16797013.6T DK16797013T DK3294323T3 DK 3294323 T3 DK3294323 T3 DK 3294323T3 DK 16797013 T DK16797013 T DK 16797013T DK 3294323 T3 DK3294323 T3 DK 3294323T3
Authority
DK
Denmark
Prior art keywords
adeno
submission
therapeutic
nervous system
central nervous
Prior art date
Application number
DK16797013.6T
Other languages
English (en)
Inventor
R Scott Mcivor
Lalitha R Belur
Karen Kozarsky
Original Assignee
Univ Minnesota
Regenxbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57320277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3294323(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Minnesota, Regenxbio Inc filed Critical Univ Minnesota
Application granted granted Critical
Publication of DK3294323T3 publication Critical patent/DK3294323T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076L-Iduronidase (3.2.1.76)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK16797013.6T 2015-05-15 2016-05-13 Adeno-associeret virus til terapeutisk indgivelse til centralnervesystemet DK3294323T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562162174P 2015-05-15 2015-05-15
US201562252055P 2015-11-06 2015-11-06
US201662301980P 2016-03-01 2016-03-01
US201662331156P 2016-05-03 2016-05-03
PCT/US2016/032392 WO2016187017A1 (en) 2015-05-15 2016-05-13 Adeno-associated for therapeutic delivery to central nervous system

Publications (1)

Publication Number Publication Date
DK3294323T3 true DK3294323T3 (da) 2022-01-10

Family

ID=57320277

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16797013.6T DK3294323T3 (da) 2015-05-15 2016-05-13 Adeno-associeret virus til terapeutisk indgivelse til centralnervesystemet

Country Status (22)

Country Link
US (5) US20180289839A1 (da)
EP (2) EP4000631A1 (da)
JP (4) JP2018515615A (da)
KR (2) KR102406615B1 (da)
CN (1) CN108367055A (da)
AU (2) AU2016263119B2 (da)
BR (1) BR112017024519A2 (da)
CA (1) CA2986252A1 (da)
CY (1) CY1125229T1 (da)
DK (1) DK3294323T3 (da)
ES (1) ES2901766T3 (da)
HK (2) HK1252871A1 (da)
HR (1) HRP20220050T1 (da)
HU (1) HUE057795T2 (da)
LT (1) LT3294323T (da)
MX (2) MX2017014443A (da)
PL (1) PL3294323T3 (da)
PT (1) PT3294323T (da)
RS (1) RS63927B1 (da)
RU (1) RU2751952C2 (da)
SI (1) SI3294323T1 (da)
WO (1) WO2016187017A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2786253T3 (es) 2013-03-14 2020-10-09 Immusoft Corp Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g
SG11201507507PA (en) 2013-03-15 2015-10-29 Univ Pennsylvania Compositions and methods for treating mpsi
KR20220119187A (ko) 2013-05-15 2022-08-26 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP4000631A1 (en) * 2015-05-15 2022-05-25 REGENXBIO Inc. Adeno-associated for therapeutic delivery to central nervous system
IL260959B2 (en) 2016-02-03 2024-09-01 Univ Pennsylvania Gene therapy for the treatment of mucoid polysaccharomyces type I
KR20190008237A (ko) * 2016-04-15 2019-01-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
EP3541946A1 (en) * 2016-11-15 2019-09-25 Regents Of The University Of Minnesota Method for improving neurological function in mpsi and mpsii and other neurological disorders
BR112019021569A2 (pt) * 2017-04-14 2020-05-12 Regenxbio Inc. Precursor de iduronato-2-sulfatase humana recombinante glicosilada (ids), método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
JP2020517692A (ja) * 2017-04-27 2020-06-18 イミュソフト コーポレーション 治療剤のin vivo送達のためのB細胞およびその投薬量
SG11201912631PA (en) * 2017-07-06 2020-01-30 Univ Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
WO2019060662A1 (en) * 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania GENE THERAPY FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSE TYPE II
BR112020006671A2 (pt) 2017-10-03 2020-12-01 Prevail Therapeutics, Inc. terapias genéticas para distúrbios lisossômicos
KR102693318B1 (ko) 2017-10-03 2024-08-07 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
EP3692158A4 (en) 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMIAL DISORDERS
AU2018375163A1 (en) * 2017-11-30 2020-06-11 The Trustees Of The University Of Pennsylvania Gene therapy for mucopolysaccharidosis IIIB
US11738093B2 (en) 2018-04-09 2023-08-29 Hope For Annabel AAV-mediated delivery of ATP1A3 genes to central nervous system
EP3823590A4 (en) * 2018-07-18 2022-04-20 REGENXBIO Inc. TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH ALL-HUMAN GLYCOSYLATED ALPHA-L-IDURONIDASE (IDUS)
KR20220006527A (ko) 2019-04-10 2022-01-17 프리베일 테라퓨틱스, 인크. 리소좀 장애에 대한 유전자 요법
CA3135539A1 (en) * 2019-05-03 2020-11-12 Juliette HORDEAUX Compositions useful in treatment of metachromatic leukodystrophy
KR20220035107A (ko) * 2019-06-10 2022-03-21 호몰로지 메디슨, 인크. Arsa 유전자 전달을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
EP4072595A1 (en) 2019-12-10 2022-10-19 Takeda Pharmaceutical Company Limited Adeno associated virus vectors for the treatment of hunter disease
MX2023001562A (es) * 2020-08-10 2023-05-03 Prevail Therapeutics Inc Terapias genicas para trastornos lisosomales.
CN117642173A (zh) * 2020-12-07 2024-03-01 华东理工大学 用于诱导对基因递送靶媒剂的免疫耐受性的方法和试剂盒
AU2022214429A1 (en) 2021-02-01 2023-09-14 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
BR112023016075A2 (pt) 2021-02-10 2023-11-21 Regenxbio Inc Método para tratar hepatoesplenomegalia, método de distribuição de um raav que codifica hids, método para tratar um sujeito humano, método de tratamento de um sujeito humano, método para determinar a eficácia do tratamento, método para identificar um sujeito como tendo mps ii
WO2022212616A1 (en) * 2021-04-01 2022-10-06 The University Of North Carolina At Chapel Hill Aav-ids vectors for treatment of mucopolysaccharidosis ii

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
DK0728214T3 (da) 1993-11-09 2004-11-29 Targeted Genetics Corp Stabile cellelinjer, der er i stand til at udtrykke det adenoassocierede virusreplikationsgen
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US5656785A (en) 1995-08-07 1997-08-12 The Charles Stark Draper Laboratory, Inc. Micromechanical contact load force sensor for sensing magnitude and distribution of loads and tool employing micromechanical contact load force sensor
EP1010228B1 (en) 1996-11-19 2007-02-28 Surgx Corporation A transient voltage protection device and method of making same
EP0950091A2 (en) 1996-12-18 1999-10-20 Targeted Genetics Corporation Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
EP1915986A1 (en) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
WO2010093784A2 (en) * 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
DK2593131T3 (da) * 2010-06-25 2019-10-14 Shire Human Genetic Therapies Fremgangsmåder og sammensætninger til cns-levering af iduronat-2-sulfatase
PT2691529T (pt) * 2011-03-31 2019-09-27 Univ Iowa Res Found Partícula de aav2 que compreende uma proteína do capsídeo de aav2 e um vetor que compreende um ácido nucleico que codifica uma tripeptidil peptidase 1 (tpp1) para utilização no tratamento da lipofuscinose ceroide infantil tardia (lincl) num mamífero não roedor por injeção intraventricular ou entrega icv
US8609088B2 (en) * 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US20130039888A1 (en) * 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
AU2012328682B2 (en) * 2011-10-27 2017-09-21 Sangamo Therapeutics, Inc. Methods and compositions for modification of the HPRT locus
KR20220119187A (ko) * 2013-05-15 2022-08-26 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
WO2015013148A2 (en) * 2013-07-26 2015-01-29 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
EP4000631A1 (en) * 2015-05-15 2022-05-25 REGENXBIO Inc. Adeno-associated for therapeutic delivery to central nervous system
EP3541946A1 (en) * 2016-11-15 2019-09-25 Regents Of The University Of Minnesota Method for improving neurological function in mpsi and mpsii and other neurological disorders

Also Published As

Publication number Publication date
EP3294323A1 (en) 2018-03-21
JP2024147704A (ja) 2024-10-16
KR20220082100A (ko) 2022-06-16
AU2016263119A1 (en) 2018-01-18
RU2017143640A (ru) 2019-06-17
MX2017014443A (es) 2018-08-01
RU2020125073A (ru) 2020-08-27
RU2751952C2 (ru) 2021-07-21
EP4000631A1 (en) 2022-05-25
AU2021266344A1 (en) 2021-12-09
RU2017143640A3 (da) 2019-11-22
MX2022012524A (es) 2022-11-16
CN108367055A (zh) 2018-08-03
CA2986252A1 (en) 2016-11-24
JP2021167332A (ja) 2021-10-21
HRP20220050T1 (hr) 2022-10-14
HK1252871A1 (zh) 2019-06-06
SI3294323T1 (sl) 2022-06-30
US20230226225A1 (en) 2023-07-20
AU2016263119B2 (en) 2021-08-12
HUE057795T2 (hu) 2022-06-28
KR20180118508A (ko) 2018-10-31
US20210369871A1 (en) 2021-12-02
AU2021266344B2 (en) 2024-08-22
LT3294323T (lt) 2022-02-25
EP3294323B1 (en) 2021-10-13
EP3294323A4 (en) 2019-01-16
HK1256341A1 (zh) 2019-09-20
PT3294323T (pt) 2022-01-06
JP2018515615A (ja) 2018-06-14
US20180071373A1 (en) 2018-03-15
RS63927B1 (sr) 2023-02-28
CY1125229T1 (el) 2023-06-09
BR112017024519A2 (pt) 2018-07-24
JP2022137261A (ja) 2022-09-21
WO2016187017A1 (en) 2016-11-24
KR102406615B1 (ko) 2022-06-08
US20220211875A1 (en) 2022-07-07
US20180289839A1 (en) 2018-10-11
ES2901766T3 (es) 2022-03-23
PL3294323T3 (pl) 2022-06-20

Similar Documents

Publication Publication Date Title
DK3294323T3 (da) Adeno-associeret virus til terapeutisk indgivelse til centralnervesystemet
DK3328880T3 (da) Terapeutiske midler
DK3265421T3 (da) Doseringssystem
MA43382A (fr) Modulateurs des récepteurs des chimiokines
DK3172227T3 (da) Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3139925T3 (da) Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser
IL266162A (en) Adeno-associated virus purification methods
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
DK3262066T4 (da) Genterapi
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112018005409A2 (pt) terapêutica de glicodirecionamento.
DK3258938T3 (da) Phenothiazinanaloger som mitokondrie terapeutiske midler
DK3393478T3 (da) Kombinationsterapi
DK3176063T3 (da) Trehjulet cykel
DK3277690T3 (da) Spirocykliske forbindelser
DK3386997T3 (da) Monomaleimid-funktionaliserede platinforbindelser til cancerterapi
CL2016000754S1 (es) Triciclo
DK3274036T3 (da) Ballonkateter til kontinuerlige nerveblokeringer
DK3374357T3 (da) Disubstituerede diaryloxybenzoheterodiazol-forbindelser
DK3096775T5 (da) SOCS-mimetika til behandling af sygdomme
ES1138645Y (es) Pieza enroscada
DK2904898T3 (da) Hestedækken
DK3329004T3 (da) Terapeutiske oligonukleotider